New Zealand markets closed

Allarity Therapeutics, Inc. (ALLR)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.1815+0.0215 (+13.44%)
At close: 04:00PM EDT
0.1735 -0.01 (-4.41%)
After hours: 07:56PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.1600
Open0.1650
Bid0.1788 x 800
Ask0.1852 x 200
Day's range0.1630 - 0.1980
52-week range0.1380 - 33.2000
Volume4,332,065
Avg. volume5,780,858
Market cap7.692M
Beta (5Y monthly)0.28
PE ratio (TTM)0.00
EPS (TTM)1,130.4700
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Allarity Therapeutics Announces Postponement of Annual Stockholders Meeting

    Boston (July 26, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, announced that its Board of Directors has decided to postpone the Annual Meeting of Stockholders, which was originally scheduled for 10:00 AM Eastern Time today, July 26, 2024. On July 25, 2024, the Board, exercising its authority under the Company’s bylaws, opted to delay the meeting to a future d

  • GlobeNewswire

    Allarity Encourages Shareholders to Vote FOR the Reverse Stock Split and Decrease in Authorized Shares

    Boston (July 24, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, encourages its stockholders to participate actively in the upcoming annual meeting of stockholders scheduled on July 26, 2024. The Company’s Board of Directors has put a proposal before stockholders for a reverse stock split. Allarity has requested approval of the reverse stock split to regain and

  • GlobeNewswire

    Allarity Therapeutics Outlines Company’s 2024 Progress and Objectives

    Current Cash Balance of $20 million Expected to Provide Runway Into 2026Allarity to Pause Use of ATMCap Table Successfully Cleaned UpAllarity’s Stenoparib Shows Extended Duration of Phase 2 Clinical Benefit Boston (July 22, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today outlines the Company’s progress in 2024 and future objectives. Led by New Management A